Pfenex Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
4,062.00
9,794.00
28,216.00
5,481.00
25,684.00
39,593
Depreciation, Depletion & Amortization
993.00
994.00
1,072.00
1,201.00
1,406.00
1,680
Other Funds
472.00
74.00
4.00
-
-
3,187
Funds from Operations
5,648.00
8,396.00
27,200.00
12,043.00
21,175.00
34,726
Changes in Working Capital
1,047.00
1,606.00
51,430.00
34,317.00
335.00
4,702
Net Operating Cash Flow
4,601.00
10,002.00
24,230.00
22,274.00
21,510.00
39,428
Capital Expenditures
119.00
316.00
1,470.00
2,868.00
2,242.00
Sale of Fixed Assets & Businesses
10.00
-
-
8.00
45.00
Purchase/Sale of Investments
2,248.00
1,250.00
-
-
-
Net Investing Cash Flow
2,357.00
934.00
1,470.00
2,860.00
2,197.00
Issuance/Reduction of Debt, Net
2,450.00
223.00
-
3,813.00
109.00
Net Financing Cash Flow
2,946.00
50,836.00
37,680.00
3,486.00
70.00
Net Change in Cash
4,012.00
41,768.00
60,440.00
28,620.00
23,637.00
Free Cash Flow
4,720.00
10,318.00
22,760.00
25,142.00
23,752.00
Deferred Taxes & Investment Tax Credit
2,719.00
-
1,955.00
1,955.00
-
-
Change in Capital Stock
24.00
50,539.00
37,684.00
327.00
179.00

About Pfenex

View Profile
Address
10790 Roselle Street
San Diego California 92121
United States
Employees -
Website http://www.pfenex.com
Updated 07/08/2019
Pfênex, Inc. is a clinical-stage biotechnology company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes biosimilars and vaccines. The company was founded on November 19, 2009 and is headquartered in San Diego, CA.